Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.Speaker 3: (00:32) Would you tell us a little bit about yourself and your history with this testing? Speaker 3: (01:25) Would you tell us a little more about this assay? Speaker 3: (04:57) Which patients should have this testing and when should it be performed?  Speaker 3: (05:30) What alternative tests exist and how do they compare? Speaker 3: (06:28) How are the results used in patient care?